Duromine vs Ozempic in the Philippines

Duromine is the legacy Philippine weight-loss brand. It is phentermine in a modified-release capsule, registered with FDA Philippines under DR-XY26998 in 15mg and 30mg strengths, and classified prescription-only. Ozempic is semaglutide, a GLP-1 receptor agonist registered for type 2 diabetes, sold through Philippine pharmacy counters at five-figure peso prices per month and prescribed off-label for weight loss more often than anybody publishes.

The reason people search for the pair together is that a Philippine doctor who has been practising for twenty years has prescribed both, and a patient sitting in front of that doctor wants to know which one they are going to be offered. The useful framing is not which drug is stronger. It is that these two answer different questions. Duromine answers “can I get through a defined three-month push”. Ozempic answers “can I be on something indefinitely”. A comparison that ignores the duration difference is comparing a sprint to a standing arrangement.

Three things are worth knowing before the table. First, the efficacy gap in the published literature is not close, and it is not close in Ozempic’s favour. Second, the peso gap runs the other way and is very large, although the Philippine half of it cannot be verified because no Philippine pharmacy publishes a Duromine price. Third, the GLP-1 side of this comparison has a supply problem that the stimulant side does not, and in mid-2026 that supply problem was rationing pens at Metro Manila counters.

Every peso figure below was read from the seller’s own live product page on 26 August 2026. Philippine pharmacy pricing moves fast, so click through and check before acting on any number here.

Sources for the cells above are listed in the sections that follow. Where a cell says not published, that is what was found, not an estimate withheld.

Duromine is phentermine. The Duromine product information describes it as a sympathomimetic amine acting on dopaminergic and noradrenergic systems, with appetite suppression “generally considered to be exerted through the hypothalamus”. In plain terms it turns down hunger by stimulating the nervous system. That is also why the side effect list reads the way it does: insomnia, nervousness, tremor, dry mouth, raised blood pressure and changes in heartbeat are the expected consequences of the mechanism, not incidental to it.

Ozempic is semaglutide, an analogue of GLP-1, a hormone your gut already releases after a meal. It works with the incretin system rather than the adrenergic one: it slows gastric emptying, amplifies glucose-dependent insulin release and acts on satiety signalling. Its side effect profile is gastrointestinal for the same reason the stimulant’s is cardiovascular. The drug is doing what its mechanism implies.

This is why the two cannot be ranked on a single axis. A patient with uncontrolled hypertension, a psychiatric history, hyperthyroidism, glaucoma or a history of substance misuse runs into the Duromine contraindication list immediately, and those are all explicit contraindications in the product information. A patient with a personal or family history of medullary thyroid carcinoma runs into the GLP-1 warnings instead. Neither list is a suggestion, and neither is something a comparison page can screen you against.

Here the two drugs are not evenly matched, and pretending otherwise would be dishonest. The Cleveland Clinic Journal of Medicine, reviewing obesity pharmacotherapy, summarised a pooled analysis of phentermine trials spanning 1975 to 1999 in which patients lost roughly 3.6kg more than those on placebo. The best single result it cites is a 36-week study with mean losses of 12.2kg on continuous phentermine against 4.8kg on placebo, which is a genuinely good outcome and also a single older study rather than a modern registration programme.

Semaglutide has that modern programme. STEP 1, published in the New England Journal of Medicine in 2021, randomised 1,961 adults with overweight or obesity and ran for 68 weeks. Mean body weight change was 14.9 percent on semaglutide 2.4mg weekly against 2.4 percent on placebo. Of the treated group, 86.4 percent lost at least 5 percent of body weight, 69.1 percent lost at least 10 percent, and 50.5 percent lost at least 15 percent, against 31.5, 12 and 4.9 percent respectively on placebo.

There is one more asymmetry worth naming. The phentermine evidence base is mostly short, mostly old, and mostly conducted before modern trial reporting standards. That does not make phentermine ineffective, and it has been in clinical use since 1959 for a reason. It does mean the comparison is between a drug with a large recent dataset and a drug with a small old one, and readers should weigh the two differently rather than reading them as equivalent evidence.

On the GLP-1 side the numbers are public and easy to check. On 26 August 2026 Watsons Philippines listed the Ozempic 0.5mg/0.37ml pen at ₱7,650 and the 1mg/0.74ml pen at ₱8,734, both flagged prescription required and both restricted to click and collect or express delivery. A pen at a given strength covers four weekly doses, so those figures are close to a monthly cost for the medicine alone, before the consultation that produces the prescription and before any bloodwork.

Manila Bulletin, reporting on 13 June 2026, recorded the same two figures and the trajectory behind them: Ozempic had moved from around ₱6,200 to ₱6,300 to the current ₱7,650 and ₱8,734, with one Las Piñas pharmacy quoting ₱11,368 for the 1mg. That report is also the clearest published account of Philippine rationing, with pharmacists describing branch limits of two pens per dosage per month and screening customers to keep supply flowing to diabetic patients.

On the Duromine side there is nothing to quote, and that is the finding. Watsons Philippines, Southstar Drug and MedsGo all publish peso prices for Ozempic, Wegovy and Mounjaro. None of the three listed Duromine when checked on 26 August 2026. The Philippine figures that circulate for it come from classified listings and forum threads, which are resale prices rather than pharmacy prices, and this site does not print those as if they were the latter. Our Duromine Philippines filing records what those channels have advertised and treats it with the same scepticism.

For scale rather than for a Philippine quote: SingleCare, updated 13 August 2026, put the average United States cash price of generic phentermine 37.5mg at about 51 dollars for 30 tablets. At roughly ₱56 to the dollar that is under ₱3,000 a month for the generic molecule in a market where a month of Ozempic costs several times that. Duromine is a branded modified-release resin formulation rather than plain generic phentermine, so it is not the same product, but the order of magnitude is the point. Stimulant appetite suppressants are cheap medicines. GLP-1 pens are not.

Prices checked 26 August 2026. Philippine pharmacy pricing changes without notice and varies by branch. Confirm at the counter before acting on any figure here.

The single most practical difference between these two drugs is not efficacy or price. It is that one of them has an expiry date written into its label and the other does not.

The Duromine product information is unambiguous: patients require medical review after a defined course of treatment, which “should not exceed three months”. It is indicated as a short-term adjunct alongside exercise, diet and behaviour modification, for people with a BMI of 30 or above, or 25 to 29.9 with additional risk. That is a defined intervention with a defined end, and the behaviour change is meant to be the durable part.

Ozempic carries no such limit because it is a chronic medicine for a chronic disease. Semaglutide trials run 68 weeks and the maintenance question afterwards is what happens when you stop, which for GLP-1 medicines is a well documented pattern of weight regain. Neither drug is a cure and neither claims to be, but they fail differently: the stimulant is designed to end, and the incretin is designed to continue, with the cost consequences that implies.

On tolerance and dependence, the literature is more measured than the internet is. The Duromine product information notes only that “inappropriate use has been reported with similar drugs and the possibility of this occurrence should be considered with Duromine”. The Cleveland Clinic Journal of Medicine, while recording that phentermine is a schedule IV controlled substance in the United States, states that concerns about addiction and dependence with phentermine are largely unfounded, and that abrupt cessation has not been shown to cause amphetamine-like withdrawal. The three-month limit is better understood as a cardiovascular and review requirement than as a withdrawal one. It is still a limit, and it is still on the label.

One side of this comparison has a supply problem. Manila Bulletin’s June 2026 report described Philippine pharmacies imposing monthly allocation limits on Ozempic, pharmacists deciding which customers to serve, patients travelling between branches, and at least one patient going a month without medication because nothing was available locally. A pharmacist quoted in that piece put it plainly: they were choosing which customers to accommodate.

That is what a five-figure annual medicine looks like when demand from off-label weight-loss prescribing meets a supply chain built for diabetes. The knock-on effects are the reason this site maintains a counterfeit Ozempic filing: when a registered channel rations, an unregistered one fills the gap, and pens bought from marketplaces and resellers are the documented counterfeit route in this region.

Duromine has the opposite problem. It is not rationed because it is not visibly stocked by the large Philippine online pharmacies at all, which pushes buyers toward exactly the same grey channels for a different reason. In both cases the correct move is the boring one: a consultation with a licensed Philippine physician, a written prescription, and a registered pharmacy that will ask to see it. Watsons, for instance, requires the prescription to be emailed for pharmacist validation before a GLP-1 order is released.